Investors & Media Press Releases
Axovant to Present at Upcoming Investor Conferences
A live webcast will be available for each conference in the Events section of Axovant's website at www.axovant.com. A replay will be available for 30 days following each conference.
Axovant is a clinical-stage neurological gene therapy company focused on developing a pipeline of clinical and nonclinical product candidates for debilitating diseases such as Parkinson's disease, oculopharyngeal muscular dystrophy, ALS, frontotemporal dementia, and other indications. Axovant is also developing small molecules for the treatment of Lewy body dementia and other neurology and psychiatry indications.
For more information, visit www.axovant.com.
SOURCE Axovant Sciences
Source: Axovant Sciences Ltd.